We need to hurry up, because cancer and patients cannot wait!
Gevorg Tamamyan, the Editor-in-chief of OncoDaily and CEO of Immune Oncology Research Institute, shared on LinkedIn:
“Just saw the presentation from ESMO GI Annual Congress and the outstanding results after neoadjuvant botensilimab and balstilimab in colorectal cancer.
The images are from a 40-year-old female with Stage 3 MSS Colorectal Cancer (CRC), after 7 weeks with BOT/BAL therapy – complete response (100% tumor reduction)!
Congratulations to all the great team of investigators – Pashtoon Kasi and colleagues and of course, wonderful Agenus team!
Waiting for similar results also from our lung cancer trial with BOT/BAL (NCT06322108), conducted by our Immune Oncology Research Institute 😉 We need to hurry up, because cancer and patients cannot wait!”
